Exelixis, Inc. (EXEL) · Oct 29, 2026 · Earnings

Exelixis earnings beat, but zanzalintinib timing slips

Beat — Non-GAAP diluted EPS $0.94 vs ~$0.89 consensus

Exelixis earnings beat Q3 revenue and adjusted EPS expectations, while unchanged 2026 guidance keeps the focus on zanzalintinib’s delayed FDA path.

Exelixis is a profitable cabozantinib-led oncology company trying to build zanzalintinib into a second commercial franchise; the quarter therefore matters less as a survival test than as evidence that the current business can fund the transition. The company’s prior-year outlook already framed 2026 around growing cabozantinib while advancing zanzalintinib toward potential commercialization.

The quarter cleared the published bar. Total revenue reached $658.7 million, about 1.9% above the published consensus of $646.5 million, while non-GAAP diluted EPS was $0.94 versus roughly $0.89 expected. The beat came on a solid cabozantinib base: net product revenue rose to $604.9 million from $542.9 million, even as collaboration revenue declined slightly.

MetricQ3 2026Q3 2025Consensus
Total revenue (Financial Statements)$658.7M (+10.2%)$597.8M$646.5M
Net product revenue (Financial Statements)$604.9M (+11.4%)$542.9M
Non-GAAP diluted EPS (Non-GAAP Reconciliation)$0.94 (+20.5%)$0.78~$0.89
GAAP diluted EPS (Income Statement)$0.85 (+23.2%)$0.69

The underlying commercial engine remains healthy, but spending is rising. Research and development expense increased to $209.5 million from $199.2 million as clinical work expanded, while SG&A rose to $154.6 million from $123.7 million on personnel, marketing, legal and advisory costs. That is consistent with a company investing ahead of a possible second franchise, not simply harvesting CABOMETYX.

The financial outlook is steady rather than upgraded. Exelixis left total revenue at $2.50 billion-$2.55 billion, net product revenue at $2.30 billion-$2.35 billion, and R&D and SG&A ranges unchanged. The one clear favorable adjustment was the effective tax-rate range, reduced to 16%-18% from 21%-23%; cost of goods sold was narrowed to approximately 4% of product revenue without changing the broader earnings narrative. This is a beat against the quarter’s consensus, not a fresh increase in the company’s operating ambition.

Zanzalintinib remains the strategic prize, but the nearest regulatory catalyst is later. The FDA’s review of the CRC application now has a March 3, 2027 PDUFA date after the review period was extended; that timing was already disclosed in September, so this filing mostly confirms rather than newly worsens the situation. 〔0〕 Exelixis also expects topline STELLAR-304 data in the first quarter of 2027, giving the pipeline a defined near-term clinical milestone. 〔1〕

Patent-settlement clarity modestly reduces uncertainty around future competition. The Azurity settlement permits a potential U.S. launch of its proposed product on December 1, 2030, while the previously established effective date for proposed generic cabozantinib products remains January 1, 2031. That is important long-term franchise timing, but it does not materially change the current-year operating story.

Bottom line: This is a clean quarterly beat from the cabozantinib business, supported by strong product revenue and lower taxes, but not a raised operating outlook. The bigger zanzalintinib story is progressing, with the key FDA decision pushed into March 2027 and already largely known to the market.

What to watch next

FDA decision on CRC NDA, March 3, 2027

Original filing on SEC EDGAR

More Exelixis, Inc. news

Exelixis earnings beat, but zanzalintinib timing slips | EXEL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.